
Relmada Therapeutics, Inc.: shareholders and insiders
Price
$2.62
November 20, 2026Market cap $280M
What Ploutos Investor adds for Relmada Therapeutics
Part of Ploutos Investor, €9.99 a month
- The full history: 13 fiscal years, from FY2012
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
Notes on these figures
- The share price has fallen 37% since Nov 12, 2026, when the 10-Q these figures come from was filed ($4.16 then, $2.62 on Nov 20, 2026). The figures date from before that move.10-Q
Insiders and their shares
Purchases and sales by officers and directors from Nov 22, 2025 to Sep 11, 2026, from their own Form 4 filings.
Bought on the market
$1.8M
2 people
Sold on the market
–
nobody
From Nov 22, 2025 to Nov 22, 2026, the days the chart shows. Change its range and the figures follow.
How the sales were made, as a share of their value
No sales in the period.
By year
Insiders' open-market purchases (up) and sales (down), by value, since Nov 22, 2025, on a log scale: each gridline is ten times the last. From the SEC's quarterly data sets of Form 4 filings.
2026·bought $1.7M by 2 people·no sales
- 2025: bought $161.4K by 2 people, no sales
- 2026: bought $1.7M by 2 people, no sales
- Sep 10, 2026Maged ShenoudaChief Financial OfficerKind
- Sep 10, 2026Sergio TraversaChief Executive OfficerKind
- Sep 9, 2026Maged ShenoudaChief Financial OfficerKind
- Sep 9, 2026Sergio TraversaChief Executive OfficerKind
| Date | Person | Kind | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Sep 10, 2026 | Maged ShenoudaChief Financial Officer | 79.8K | $4.25 | $339.2K | Form 4 | |
| Sep 10, 2026 | Sergio TraversaChief Executive Officer | 100.0K | $4.10 | $410.0K | Form 4 | |
| Sep 9, 2026 | Maged ShenoudaChief Financial Officer | 120.2K | $4.20 | $504.8K | Form 4 | |
| Sep 9, 2026 | Sergio TraversaChief Executive Officer | 100.0K | $4.18 | $418.0K | Form 4 |
From the Form 4s insiders file with the SEC within two business days of each trade. Before Sep 11, 2026 the table lists open-market purchases and sales only (no grants, option exercises or tax withholding), from the SEC's quarterly data sets. The 10b5-1 mark comes from the form's own box (since April 2023) or from a footnote of the filing that names the plan, where there is one.
Insiders and their shares
Every buy and sale by RLMD's officers and directors from 2015 up to November 21, 2025, 11 more calendar years
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 3 years.
and 6 more, back to 2015
Major holders (over 5%)
Whoever comes to own more than 5% of a class of shares reports it to the SEC on Schedule 13D or 13G. Here is each holder's latest filing.
- Janus Henderson GroupShare of class10.1%
- BlackRock, Inc.Share of class7.00%
- Squadron Master Fund LPwith 3 more personsShare of class7.00%
- Venrock Healthcare Capital Partners III, L.P.with 6 more personsShare of class6.20%
- Spruce Street Capital LPwith 2 more personsShare of class5.57%
- Commodore Capital LPwith 3 more personsShare of class5.10%
| Holder | Kind of stake | Share of class | Shares | Filed | Filing |
|---|---|---|---|---|---|
| Janus Henderson Group | 10.1% | 7.44M | Feb 6, 2026 | 13G | |
| BlackRock, Inc. | 7.00% | 7.35M | Jul 29, 2026 | 13G | |
| Squadron Master Fund LPwith 3 more persons | 7.00% | 7.35M | Aug 14, 20264 filings since May 1, 2025 | 13G/A | |
| Venrock Healthcare Capital Partners III, L.P.with 6 more persons | 6.20% | 6.51M | Jun 9, 2026 | 13G | |
| Spruce Street Capital LPwith 2 more persons | 5.57% | 4.09M | Feb 17, 2026 | 13G | |
| Commodore Capital LPwith 3 more persons | 5.10% | 5.51M | May 4, 2026 | 13G |
Fell to 5% or less (3)
Holders whose latest filing says they hold 5% or less. After it they need not file again, so what they hold today is not known.
From the Schedule 13D and 13G filed with the SEC since Dec 18, 2024, when they became structured data. A holder who has filed nothing since then is not shown here. A 13D is updated within two business days of any material change, a 13G up to 45 days after the quarter of the change, so the shares are those of the filing. The large managers also appear in the 13Fs.
Well-known managers
Which of the about 30 investment managers we track held the shares at the quarter end, and what they changed from the quarter before.
- Millennium Mgmt (Englander)In the quarter+42%
- Citadel Advisors (Griffin)In the quarter-58%
- D.E. ShawIn the quarter+282%
- Renaissance TechnologiesIn the quarter+771%
- AQR CapitalIn the quarter
| Manager | Shares | In the quarter | Value | % of their portfolio |
|---|---|---|---|---|
| Millennium Mgmt (Englander) | 3.35M | +42% | $13M | 0.01% |
| Citadel Advisors (Griffin) | 442.1K | -58% | $1.7M | 0.00% |
| D.E. Shaw | 418.4K | +282% | $1.6M | 0.00% |
| Renaissance Technologies | 503.2K | +771% | $1.9M | 0.00% |
| AQR Capital | 74.5K | $300.0K | 0.00% |
From the 13Fs managers file with the SEC up to 45 days after each quarter end. They show only long positions on that day, not short sales or what has changed since. No recent 13F: Pershing Square (Ackman), Scion (Burry).
Short interest
How many of the company's shares have been sold borrowed and not yet bought back, twice a month.
On Oct 15, 2026, 11.4% of its shares outstanding were held short, -9.3% since the report before.
- Shares held short
- 12.18M
- 11.4%
- Since the report before13.42M on Sep 30, 2026
- -9.3%
- 8.5
- 1.43M
- More days to cover thanof 4,578 US-listed companies with enough volume
- 86%
- Report date
- Oct 15, 2026
- Shares held short
- Oct 31, 2023: Shares held short 794.7K
- Nov 15, 2023: Shares held short 875.2K
- Nov 30, 2023: Shares held short 865.8K
- Dec 15, 2023: Shares held short 638.8K
- Dec 29, 2023: Shares held short 810.6K
- Jan 12, 2024: Shares held short 1.56M
- Jan 31, 2024: Shares held short 1.61M
- Feb 15, 2024: Shares held short 1.73M
- Feb 29, 2024: Shares held short 1.75M
- Mar 15, 2024: Shares held short 1.75M
- Mar 28, 2024: Shares held short 1.69M
- Apr 15, 2024: Shares held short 1.71M
- Apr 30, 2024: Shares held short 1.64M
- May 15, 2024: Shares held short 1.57M
- May 31, 2024: Shares held short 1.54M
- Jun 14, 2024: Shares held short 1.55M
- Jun 28, 2024: Shares held short 1.01M
- Jul 15, 2024: Shares held short 1.36M
- Jul 31, 2024: Shares held short 1.33M
- Aug 15, 2024: Shares held short 1.29M
- Aug 30, 2024: Shares held short 1.21M
- Sep 13, 2024: Shares held short 1.18M
- Sep 30, 2024: Shares held short 1.25M
- Oct 15, 2024: Shares held short 1.26M
- Oct 31, 2024: Shares held short 1.19M
- Nov 15, 2024: Shares held short 1.15M
- Nov 29, 2024: Shares held short 1.06M
- Dec 13, 2024: Shares held short 1.78M
- Dec 31, 2024: Shares held short 1.65M
- Jan 15, 2025: Shares held short 1.25M
- Jan 31, 2025: Shares held short 838.0K
- Feb 14, 2025: Shares held short 1.75M
- Feb 28, 2025: Shares held short 1.26M
- Mar 14, 2025: Shares held short 1.49M
- Mar 31, 2025: Shares held short 1.62M
- Apr 15, 2025: Shares held short 1.41M
- Apr 30, 2025: Shares held short 2.03M
- May 15, 2025: Shares held short 1.22M
- May 30, 2025: Shares held short 1.13M
- Jun 13, 2025: Shares held short 695.5K
- Jun 30, 2025: Shares held short 595.0K
- Jul 15, 2025: Shares held short 423.9K
- Jul 31, 2025: Shares held short 401.3K
- Aug 15, 2025: Shares held short 478.4K
- Aug 29, 2025: Shares held short 557.3K
- Sep 15, 2025: Shares held short 711.3K
- Sep 30, 2025: Shares held short 835.7K
- Oct 15, 2025: Shares held short 562.4K
- Oct 31, 2025: Shares held short 514.1K
- Nov 14, 2025: Shares held short 946.5K
- Nov 28, 2025: Shares held short 772.9K
- Dec 15, 2025: Shares held short 980.7K
- Dec 31, 2025: Shares held short 1.39M
- Jan 15, 2026: Shares held short 1.43M
- Jan 30, 2026: Shares held short 1.26M
- Feb 13, 2026: Shares held short 1.11M
- Feb 27, 2026: Shares held short 836.3K
- Mar 13, 2026: Shares held short 3.73M
- Mar 31, 2026: Shares held short 6.04M
- Apr 15, 2026: Shares held short 6.19M
- Apr 30, 2026: Shares held short 5.35M
- May 15, 2026: Shares held short 5.49M
- May 29, 2026: Shares held short 5.84M
- Jun 15, 2026: Shares held short 6.06M
- Jun 30, 2026: Shares held short 10.65M
- Jul 15, 2026: Shares held short 12.99M
- Jul 31, 2026: Shares held short 13.56M
- Aug 14, 2026: Shares held short 12.89M
- Aug 31, 2026: Shares held short 13.60M
- Sep 15, 2026: Shares held short 14.46M
- Sep 30, 2026: Shares held short 13.42M
- Oct 15, 2026: Shares held short 12.18M
As brokers report them to the regulator twice a month, mid-month and at month end, published about eight business days later. A short position is shares sold borrowed and not yet bought back. The share count is the one the company's market value is figured on, from its filings. Days to cover is the shares held short over the average daily volume of the weeks between two reports.
Short sales in daily trading54.0% of the shares in the last 14 sessions' reported trades were short sales.
In the last 14 sessions, 54.0% of the shares in the reported trades were short sales, against 43.6% in the 14 before.
- Last 14 sessionsNov 3, 2026 – Nov 20, 2026
- 54.0%
- The 14 beforeOct 14, 2026 – Nov 2, 2026
- 43.6%
- Change
- +10.4 pts
- Short sales a dayon average, of 607.0K shares
- 327.5K
- More than atof 3,666 US-listed companies, same days
- 63%
- Median of alleight in ten from 34.4% to 63.9%
- 50.5%
- Short sales
- Oct 14, 2026: Short sales 50.3%
- Oct 15, 2026: Short sales 67.9%
- Oct 16, 2026: Short sales 81.8%
- Oct 19, 2026: Short sales 64.7%
- Oct 20, 2026: Short sales 61.6%
- Oct 21, 2026: Short sales 53.8%
- Oct 22, 2026: Short sales 15.7%
- Oct 23, 2026: Short sales 76.6%
- Oct 26, 2026: Short sales 60.5%
- Oct 27, 2026: Short sales 29.3%
- Oct 28, 2026: Short sales 43.9%
- Oct 29, 2026: Short sales 29.5%
- Oct 30, 2026: Short sales 63%
- Nov 2, 2026: Short sales 77.8%
- Nov 3, 2026: Short sales 53.9%
- Nov 4, 2026: Short sales 50.6%
- Nov 5, 2026: Short sales 51.5%
- Nov 6, 2026: Short sales 55.2%
- Nov 9, 2026: Short sales 58%
- Nov 10, 2026: Short sales 78.3%
- Nov 11, 2026: Short sales 62.8%
- Nov 12, 2026: Short sales 61.9%
- Nov 13, 2026: Short sales 63.7%
- Nov 16, 2026: Short sales 34.9%
- Nov 17, 2026: Short sales 61.1%
- Nov 18, 2026: Short sales 50.5%
- Nov 19, 2026: Short sales 60.7%
- Nov 20, 2026: Short sales 49.3%
This is not the number of shares sold short today: it measures short sales within each day's trading, and only trades made off the exchanges. Much of it is market makers, who sell shares they do not have to fill buyers' orders and cover soon after, so for a heavily traded stock the share is often around half.
What the insiders hold
The shares each insider reports holding after their latest trade (Form 4), for those who traded on the market in the last three years.
- Sergio TraversaChief Executive OfficerDirectly1.50M
- Maged ShenoudaChief Financial OfficerDirectly1.00M
- Paul Edward KellyChief Operating OfficerDirectly502.3K
- Chuck EnceCAO and COODirectly403.9K
- Charles J CasamentoDirectorDirectly13.0K
| Person | Directly | Indirectly | After the trade of | Filing |
|---|---|---|---|---|
| Sergio TraversaChief Executive Officer | 1.50M | – | Sep 10, 2026 | Form 4 |
| Maged ShenoudaChief Financial Officer | 1.00M | – | Sep 10, 2026 | Form 4 |
| Paul Edward KellyChief Operating Officer | 502.3K | – | Nov 5, 2025 | Form 4 |
| Chuck EnceCAO and COO | 403.9K | – | Nov 5, 2025 | Form 4 |
| Charles J CasamentoDirector | 13.0K | – | Sep 9, 2024 | Form 4 |
A lower bound: it counts only the 5 officers and directors with a market trade since Nov 23, 2023. Anyone who neither bought nor sold since is not here, whatever they hold. The share is against the share count on the latest 10-K's cover.
The ETFs that hold it
Which of the 349 US equity ETFs we track hold the stock, and at what weight, from the funds' N-PORT filings.
- IWCiShares Micro-Cap ETFWeight in the fund0.14%
- IWOiShares Russell 2000 Growth ETFWeight in the fund0.04%
- IWMiShares Russell 2000 ETFWeight in the fund0.02%
- VTWOVanguard Russell 2000 Index FundWeight in the fund0.01%
- VXFVanguard Extended Market Index FundWeight in the fund0.01%
- VHTVanguard Health Care Index FundWeight in the fund0.00%
- ITOTiShares Core S&P Total U.S. Stock Market ETFWeight in the fund0.00%
- ONEQFidelity Nasdaq Composite Index ETFWeight in the fund0.00%
- IWViShares Russell 3000 ETFWeight in the fund0.00%
- VTIVanguard Total Stock Market Index FundWeight in the fund0.00%
10 of the 349 ETFs we track, not of every ETF on the market. The ten largest weights. Positions as each fund filed them in its latest N-PORT.
Institutional investors by quarter
Every manager that reports positions to the SEC (Form 13F), quarter by quarter: how many hold the stock, how many shares and dollars between them, and who entered, left, added or trimmed during the quarter.
- Managers
- Q3 2025: Managers 44
- Q4 2025: Managers 78
- Q1 2026: Managers 104
- Q2 2026: Managers 126
Institutional investors by quarter
The fund managers holding RLMD, quarter by quarter, from Q2 2016 to Q2 2025, 24 more quarters
Part of Ploutos Investor, €9.99 a month
Sign in with a free account to see the last 12 quarters.
Q2 2026: 126 managers held 100M shares, worth $694M. During the quarter 46 opened a position, 25 closed one, 34 added and 22 trimmed.
The largest holders, Q2 2026
- Jupiter TopcoIn the quarter
- BlackRockIn the quarter+476%
- Squadron Capital ManagementIn the quarter-13%
- Venrock AdviserIn the quarter+41%
- Spruce Street CapitalIn the quarter+2.1%
- Adage Capital Partners GpIn the quarter
- Vanguard Capital ManagementIn the quarter+45%
- Jones Hill CapitalIn the quarter×10.7
- Orbimed AdvisorsIn the quarter-23%
- State StreetIn the quarter+605%
| Manager | Shares | In the quarter | Value |
|---|---|---|---|
| Jupiter Topco | 11.16M | $77M | |
| BlackRock | 7.43M | +476% | $51M |
| Squadron Capital Management | 7.35M | -13% | $51M |
| Venrock Adviser | 6.84M | +41% | $47M |
| Spruce Street Capital | 6.39M | +2.1% | $44M |
| Adage Capital Partners Gp | 4.76M | $33M | |
| Vanguard Capital Management | 4.46M | +45% | $31M |
| Jones Hill Capital | 3.66M | ×10.7 | $25M |
| Orbimed Advisors | 3.63M | -23% | $25M |
| State Street | 2.52M | +605% | $17M |
From the SEC's Form 13F data sets, Q3 2025 to Q2 2026: the long positions of every manager with more than $100 million under management, as filed up to 45 days after each quarter end. Short positions and options are not in them. Shares as reported each quarter, not adjusted for splits. The stock is matched by its CUSIP, through the SEC's fails-to-deliver files.
Pay against performance, the say-on-pay vote, buybacks by quarter and trading plans are read for S&P 500 companies only.
The full analysis
What do Relmada Therapeutics's filings show?
Who buys and sells is one part of Relmada Therapeutics's picture. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Have RLMD's insiders bought or sold?
From Sep 11, 2026 to Sep 11, 2026 Relmada Therapeutics's insiders bought $1.7M and sold 0 of shares on the market. – of the sales were under set 10b5-1 plans.
Which well-known managers hold RLMD?
5 of the managers we track held the shares on Sep 30, 2026. The largest position was Millennium Mgmt (Englander)'s, worth $13M.
Is every insider transaction a purchase or a sale?
No. Many are part of their pay: share awards, option exercises and shares the company keeps for the tax. Only code P is a purchase with their own money, and code S a sale on the market.
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.